Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)-Reference-Cited by-同舟云学术

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)

Published:2018-04 Issue:4 Volume:29 Page:1004-1009
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Tahara M.,Kiyota N.,Yokota T.,Hasegawa Y.,Muro K.,Takahashi S.,Onoe T.,Homma A.,Taguchi J.,Suzuki M.,Minato K.,Yane K.,Ueda S.,Hara H.,Saijo K.,Yamanaka T.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/4/1004/24702775/mdy040.pdf

Reference16 articles.

1. Estimates of the worldwide incidence of 25 major cancers in 1990;Parkin;Int J Cancer,1999

2. Platinum-based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008

3. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Gregoire;Ann Oncol,2010

4. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017;Adelstein;J Natl Compr Canc Netw,2017

5. Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer. In 2007 ASCO Annual Meeting;Buentzel;J Clin Oncol,2007

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer;Pharmaceutics;2024-09-11

2. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial;Journal of Clinical Oncology;2024-09-01

3. Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: a retrospective analysis from two institutions in India;F1000Research;2024-07-15

4. Identification of activating transcription factor 6 (ATF6) as a novel prognostic biomarker and potential target in oral squamous cell carcinoma;Gene;2024-07

5. Therapeutic options for skin cancers: BCC, SCC, MCC and DFSP;Dermatologie pro praxi;2024-06-03